Equity Vii L.P. Spectrum Sells 10,677 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm's stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total transaction of $51,249.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Equity Vii L.P. Spectrum also recently made the following trade(s):

• On Friday, June 6th, Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock. The stock was sold at an average price of $4.09, for a total value of $43,668.93.

GoodRx Stock Down 5.8%

Shares of GoodRx stock traded down $0.29 during trading on Friday, reaching $4.76. The company's stock had a trading volume of 2,817,927 shares, compared to its average volume of 1,426,463. GoodRx Holdings, Inc. has a 1-year low of $3.68 and a 1-year high of $9.26. The company has a 50-day simple moving average of $4.34 and a two-hundred day simple moving average of $4.52. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 0.74. The company has a market cap of $1.70 billion, a price-to-earnings ratio of 59.49, a P/E/G ratio of 2.25 and a beta of 1.24.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. The business had revenue of $202.97 million for the quarter, compared to analyst estimates of $202.25 million. GoodRx had a return on equity of 7.85% and a net margin of 3.57%. The company's revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.08 earnings per share. As a group, equities analysts forecast that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

Wall Street Analyst Weigh In

GDRX has been the subject of several research reports. Wells Fargo & Company lowered their target price on GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Truist Financial decreased their price objective on GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a report on Thursday, April 10th. UBS Group dropped their target price on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Finally, The Goldman Sachs Group reduced their price target on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Five equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, GoodRx has a consensus rating of "Moderate Buy" and a consensus target price of $6.55.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in GoodRx by 9.1% in the 4th quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company's stock worth $4,986,000 after acquiring an additional 89,032 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in GoodRx during the 4th quarter worth approximately $358,000. Barclays PLC lifted its stake in GoodRx by 18.4% during the 4th quarter. Barclays PLC now owns 165,928 shares of the company's stock valued at $772,000 after acquiring an additional 25,815 shares during the period. Northern Trust Corp lifted its stake in GoodRx by 13.5% during the 4th quarter. Northern Trust Corp now owns 421,810 shares of the company's stock valued at $1,961,000 after acquiring an additional 50,256 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of GoodRx by 10.1% in the 4th quarter. Bank of New York Mellon Corp now owns 192,612 shares of the company's stock valued at $896,000 after acquiring an additional 17,633 shares during the last quarter. Hedge funds and other institutional investors own 63.77% of the company's stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.